These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 31126817)

  • 21. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
    Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
    Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T
    Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
    Zhu K; Du D; Yang R; Tao H; Zhang H
    Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of histone methylation by automethylation of PRC2.
    Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR
    Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.
    Hsu JH; Rasmusson T; Robinson J; Pachl F; Read J; Kawatkar S; O' Donovan DH; Bagal S; Code E; Rawlins P; Argyrou A; Tomlinson R; Gao N; Zhu X; Chiarparin E; Jacques K; Shen M; Woods H; Bednarski E; Wilson DM; Drew L; Castaldi MP; Fawell S; Bloecher A
    Cell Chem Biol; 2020 Jan; 27(1):41-46.e17. PubMed ID: 31786184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
    Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
    Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.
    Svrlanska A; Reichel A; Schilling EM; Scherer M; Stamminger T; Reuter N
    J Virol; 2019 May; 93(9):. PubMed ID: 30814291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
    Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
    Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disruption of FOXP3-EZH2 Interaction Represents a Pathobiological Mechanism in Intestinal Inflammation.
    Bamidele AO; Svingen PA; Sagstetter MR; Sarmento OF; Gonzalez M; Braga Neto MB; Kugathasan S; Lomberk G; Urrutia RA; Faubion WA
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):55-71. PubMed ID: 30510991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrations of EZH2 in cancer.
    Chase A; Cross NC
    Clin Cancer Res; 2011 May; 17(9):2613-8. PubMed ID: 21367748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
    Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
    Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
    Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
    Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex.
    Cao R; Zhang Y
    Mol Cell; 2004 Jul; 15(1):57-67. PubMed ID: 15225548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.
    Wu H; Zeng H; Dong A; Li F; He H; Senisterra G; Seitova A; Duan S; Brown PJ; Vedadi M; Arrowsmith CH; Schapira M
    PLoS One; 2013; 8(12):e83737. PubMed ID: 24367611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The deletion of the protein phosphatase 1 regulator NIPP1 in testis causes hyperphosphorylation and degradation of the histone methyltransferase EZH2.
    Ferreira M; Verbinnen I; Fardilha M; Van Eynde A; Bollen M
    J Biol Chem; 2018 Nov; 293(47):18031-18039. PubMed ID: 30305391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
    Mahara S; Lee PL; Feng M; Tergaonkar V; Chng WJ; Yu Q
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3735-44. PubMed ID: 27303043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.
    Potjewyd F; Turner AW; Beri J; Rectenwald JM; Norris-Drouin JL; Cholensky SH; Margolis DM; Pearce KH; Herring LE; James LI
    Cell Chem Biol; 2020 Jan; 27(1):47-56.e15. PubMed ID: 31831267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic Protein Interactions of the Polycomb Repressive Complex 2 during Differentiation of Pluripotent Cells.
    Oliviero G; Brien GL; Waston A; Streubel G; Jerman E; Andrews D; Doyle B; Munawar N; Wynne K; Crean J; Bracken AP; Cagney G
    Mol Cell Proteomics; 2016 Nov; 15(11):3450-3460. PubMed ID: 27634302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
    Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
    Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
    Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.